The analysts flag several key factors that could influence these stocks' performance and impact their earnings reports.
As a result, they anticipate that the company may revise its guidance downward, particularly as its EBIT for the first half of the year only achieved 47% of consensus expectations. Despite its strong market position, Novartis is grappling with sector-specific challenges, as healthcare equipment and biotechnology have seen mixed performance across Europe in recent months.), are positioned for potential positive surprises. UBS believes that IAG could exceed expectations, driven by a strong first-half EBIT performance, which accounted for 35% of its annual guidance.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Fonte: Investingcom - 🏆 450. / 53 Consulte Mais informação »